Blueprint Medicines Co. (NASDAQ:BPMC) Receives $123.33 Average Price Target from Analysts

Blueprint Medicines Co. (NASDAQ:BPMC) has received a consensus recommendation of “Moderate Buy” from the twenty brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $123.33.

A number of equities analysts recently commented on the stock. Stephens reaffirmed an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. HC Wainwright reiterated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, November 15th. JMP Securities reissued a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Monday, December 9th. UBS Group started coverage on Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, November 15th.

Blueprint Medicines Trading Down 4.0 %

Shares of NASDAQ BPMC opened at $90.63 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. Blueprint Medicines has a 12 month low of $72.24 and a 12 month high of $121.90. The company has a market cap of $5.76 billion, a price-to-earnings ratio of -42.95 and a beta of 0.61. The business has a fifty day simple moving average of $93.48 and a 200-day simple moving average of $95.63.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The company had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business’s quarterly revenue was up 126.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.20) earnings per share. Sell-side analysts predict that Blueprint Medicines will post -3.68 EPS for the current year.

Insider Activity

In other Blueprint Medicines news, CEO Kate Haviland sold 2,353 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $96.60, for a total transaction of $227,299.80. Following the transaction, the chief executive officer now owns 150,824 shares in the company, valued at $14,569,598.40. This trade represents a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $95.91, for a total transaction of $218,099.34. Following the completion of the sale, the chief operating officer now owns 69,383 shares of the company’s stock, valued at $6,654,523.53. The trade was a 3.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,720 shares of company stock valued at $2,177,846. Insiders own 4.21% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the business. Exome Asset Management LLC bought a new stake in Blueprint Medicines during the 3rd quarter valued at approximately $3,395,000. Franklin Resources Inc. lifted its holdings in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after buying an additional 265 shares during the last quarter. Synovus Financial Corp boosted its position in shares of Blueprint Medicines by 4.0% in the third quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock valued at $2,224,000 after acquiring an additional 922 shares during the period. Sanctuary Advisors LLC acquired a new stake in shares of Blueprint Medicines in the third quarter worth $202,000. Finally, Teachers Retirement System of The State of Kentucky increased its position in Blueprint Medicines by 23.7% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 16,520 shares of the biotechnology company’s stock worth $1,528,000 after acquiring an additional 3,162 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.